Status:
COMPLETED
Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Non-adherence to the treatment regimen is a common problem associated with injectable drugs (e.g. Betaferon) that are used in multiple sclerosis patients. Certain patients omit single injections or e...
Eligibility Criteria
Inclusion
- Relapsing-remitting multiple sclerosis
- Age \>/= 18 years
- Start of treatment with Betaferon not earlier than 60 days prior to inclusion
Exclusion
- Synonymous with contraindications to Betaferon
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
852 Patients enrolled
Trial Details
Trial ID
NCT01184833
Start Date
September 1 2008
End Date
August 1 2011
Last Update
June 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Poland